Stockholm – October 15, 2018 – According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee for the annual general meeting 2019 shall be composed of members appointed by t... read more

15 October 2018  at 07:16:00  CET 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation OSLO, Norway, Oct. 15... read more

Paris, France, October 12, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced to... read more

Stockholm – October 12, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), the presentation will be webcasted. Oncopeptides is a research and development stage p... read more

Oslo, Norway, 12 October 2018 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Associat... read more